Novo Nordisk Says ‍Victoza Significantly Reduces Risk of Major Adverse Cardiovascular Events in Leader Tria; Says ‍Safety Profile of Victoza in Leader Was Generally Consistent With Previous Liraglutide Clinical Studies
Charles Gross